BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10073370)

  • 1. Outcome in schizophrenia: beyond symptom reduction.
    Meltzer HY
    J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medico-economic study of LĂ©ponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
    Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
    Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vs. old antipsychotics: the Texas experience.
    Reid WH
    J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual health outcomes and treatment costs for schizophrenia populations.
    Mauskopf JA; David K; Grainger DL; Gibson PJ
    J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antipsychotic agents: emerging clinical profiles.
    Buckley PF
    J Clin Psychiatry; 1999; 60 Suppl 1():12-7; discussion 28-30. PubMed ID: 10037165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
    Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
    Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
    Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
    J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.
    Hellewell JS
    J Clin Psychiatry; 1999; 60 Suppl 23():14-9. PubMed ID: 10625195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine for refractory schizophrenia: the Illinois experience.
    Buckman RW; Malan RD
    J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine].
    Gosselin O; Ribeyre JM; Kahn JP
    Encephale; 1997 Sep; 23 Spec No 4():2-6. PubMed ID: 9417400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacoeconomics of clozapine: a review.
    Meltzer HY; Cola PA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug treatment history on comparative effectiveness research in schizophrenia.
    McCombs J; Zolfaghari S; Ganapathy V
    Value Health; 2011; 14(5):679-86. PubMed ID: 21839406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.